Clinical TrialMay 12, 2026, 09:33 AM
Cogent Biosciences APEX Trial Data Accepted for Oral Presentation
AI Summary
Cogent Biosciences announced that pivotal data from its APEX trial for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) has been accepted for an oral presentation at the European Hematology Association (EHA) Congress. This marks the company's third oral presentation of pivotal data for bezuclastinib at a major medical meeting. Additionally, preclinical data from its emerging JAK2 V617F program will be presented as a poster at the same congress, highlighting the company's progress in developing precision therapies.
Key Highlights
- Pivotal data from the APEX trial for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) accepted for oral presentation at EHA Congress.
- This marks Cogent's third oral presentation of pivotal data for bezuclastinib at major medical meetings.
- Oral presentation by Dr. Daniel DeAngelo on June 13, 2026, 17:15 – 18:30 CEST.
- A poster presentation on bezuclastinib's effect on AdvSM pathobiology from the APEX trial will be presented by Dr. Tracy George on June 12, 2026.
- Preclinical data for CGT1145, a novel JAK2 V617F mutant-selective inhibitor, accepted for poster presentation by Mark J Chicarelli on June 12, 2026.
Price Impact
More from COGT